LWA
RPTX

Lantern Wealth Advisors’s Repare Therapeutics RPTX Stock Holding History

Lantern Wealth Advisors’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$35.2K – 174
2025
Q3 		$35.2K Buy
+20,000
New +$32K 0.02% 156

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Lantern Wealth Advisors's RPTX Position: Q4 2025 in Review

Lantern Wealth Advisors sold out of Repare Therapeutics (RPTX) in Q4 2025, closing a stake of 20,000 shares — an estimated $35.2K sold.

Lantern Wealth Advisors first reported a position in RPTX in Q3 2025 and held it in 1 quarter. The position peaked at $35.2K in Q3 2025. 46 funds tracked by Wall St. Rank hold RPTX as of Q4 2025.

  • Lantern Wealth Advisors reported no remaining Repare Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lantern Wealth Advisors sold 20,000 Repare Therapeutics shares in Q4 2025, an estimated $35.2K.
  • Lantern Wealth Advisors first reported a position in Repare Therapeutics in Q3 2025 and held it in 1 quarter.
  • Lantern Wealth Advisors's Repare Therapeutics position peaked at $35.2K in Q3 2025.
  • 46 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2025.

Based on Lantern Wealth Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.